The new hypoglycemic mechanism and other effects of metformin.
- VernacularTitle:二甲双胍新降糖机制及其降糖以外作用
- Author:
Huanhuan CHEN
;
Hongwen ZHOU
;
Chao LIU
- Publication Type:Journal Article
- Keywords:
metformin;
dipeptidyl peptidase Ⅳ;
polycystic ovary syndrome;
non-alcoholic fatty liver disease
- From:
Chinese Journal of Practical Internal Medicine
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Metformin has been applied for 50 year.In recent years,new studies found that metformin could reduce glucose through activating inhibition of dipeptidyl peptidase Ⅳ(DPP Ⅳ) and enhancing the biological effect of glucagon-like peptide-1(GLP-1).In addition,metformin can reduce vascular disease risk of patients with type 2 diabetes by improving insulin resistance and the effect of reducing total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),blood coagulation factor Ⅶ,plasminogen activator inhibitor-1(PAI-1) and proteinuria.Merformin can't change blood pressure of patients with type 2 diabetes,however,it can significantly reduce the salt-sensitive blood pressure of patients with obesity.Metformin has also been applied to patients with polycystic ovary syndrome(PCOS).It can induce ovulation,decrease the rate of abortion and have effect on hypertrichosis and hyperandrogenism.Besides,metformin has been the focus of the treatment of non-alcoholic fatty liver disease.
